Saturday, October 31, 2026

Pfizer And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Pfizer  And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - Pfizer (PFE), Lennar Corporation (LEN), Baxter International (BAX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Pfizer (PFE)

62.5% sales growth and 14.03% return on equity

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.

Pfizer's sales growth this year is expected to be 74.9% and a negative 15% for next year.

Year-on-year quarterly revenue growth grew by 44.6%, now sitting on 46.41B for the twelve trailing months.

Volume

Today's last reported volume for Pfizer is 44829400 which is 73.65% above its average volume of 25816200.

Pfizer's sales growth for the next quarter is 62.5%. The company's growth estimates for the ongoing quarter and the next is 25.6% and 44.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.03%.

Volatility

Pfizer's last day, last week, and last month's current volatility was 0.05%, 1.16%, and 0.79%, respectively.

Pfizer's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.17% (day), 1.82% (last week), and 1.51% (last month), respectively.

Pfizer's Stock Yearly Top and Bottom Value

Pfizer's stock is valued at $45.68 at 06:22 EST, higher than its 52-week high of $45.52.

Pfizer's Moving Average

Pfizer's worth is way higher than its 50-day moving average of $40.16 and way above its 200-day moving average of $37.77.

Previous days news about Pfizer(PFE)

According to Bloomberg Quint on Friday, 30 July, "He said that the government in September expects 647,000 doses of the Pfizer vaccine from the U.S., 688,000 of the AstraZeneca jab from the COVAX Facility, and 299,000 doses from the U.K."

According to The Motley Fool on Friday, 30 July, "Moderna's projected sales this year are only a fraction of what Pfizer will likely make. ", "However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined."

According to Business Insider on Friday, 30 July, "It was originally Pfizer Bangladesh before Pfizer transferred the ownership of the subsidiary to the local operating family," he said. "

FDA puts all hands on deck to review Pfizer-biontech covid shot. According to Bloomberg Quint on Friday, 30 July, "U.S. drug regulators are taking an "all-hands-on-deck approach" to reviewing Pfizer Inc. and BioNTech SE's Covid-19 shot for full approval in an effort to persuade as many as possible to get immunized."

2. Lennar Corporation (LEN)

31.2% sales growth and 18.79% return on equity

Lennar Corporation, together with its subsidiaries, operates as a homebuilder primarily under the Lennar brand in the United States.

Lennar Corporation's sales growth this year is anticipated to be 18.6% and 12.4% for next year.

Year-on-year quarterly revenue growth grew by 21.6%, now sitting on 24.45B for the twelve trailing months.

Volume

Today's last reported volume for Lennar Corporation is 1245310 which is 49.16% below its average volume of 2449350.

Lennar Corporation's sales growth is a negative 0% for the present quarter and 31.2% for the next. The company's growth estimates for the ongoing quarter and the next is 54.7% and 60.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.79%.

Volatility

Lennar Corporation's last day, last week, and last month's current volatility was 1.26%, 2.17%, and 1.67%, respectively.

Lennar Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.62% (day), 3.16% (last week), and 2.58% (last month), respectively.

Lennar Corporation's Stock Yearly Top and Bottom Value

Lennar Corporation's stock is valued at $107.29 at 06:22 EST, below its 52-week high of $110.61 and way higher than its 52-week low of $69.41.

Lennar Corporation's Moving Average

Lennar Corporation's worth is way higher than its 50-day moving average of $97.38 and way above its 200-day moving average of $94.70.

3. Baxter International (BAX)

13.5% sales growth and 13.28% return on equity

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products.

Baxter International's sales growth this year is expected to be 8.4% and 5.2% for next year.

Year-on-year quarterly revenue growth grew by 5.1%, now sitting on 11.82B for the twelve trailing months.

Volume

Today's last reported volume for Baxter International is 4418540 which is 58.61% above its average volume of 2785730.

Baxter International's sales growth for the next quarter is 13.5%. The company's growth estimates for the present quarter and the next is 15.6% and 13.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.28%.

Volatility

Baxter International's last day, last week, and last month's current volatility was 0.04%, 1.65%, and 0.86%, respectively.

Baxter International's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.11% (day), 3.16% (last week), and 1.72% (last month), respectively.

Baxter International's Stock Yearly Top and Bottom Value

Baxter International's stock is valued at $76.28 at 06:22 EST, way under its 52-week high of $88.32 and above its 52-week low of $74.79.

Baxter International's Moving Average

Baxter International's value is below its 50-day moving average of $81.04 and below its 200-day moving average of $81.56.

4. National Bankshares (NKSH)

8.1% sales growth and 8.86% return on equity

National Bankshares, Inc. operates as the bank holding company for the National Bank of Blacksburg that provides retail and commercial banking products and services to individuals, businesses, non-profits, and local governments.

National Bankshares's sales growth this year is expected to be 6.3% and a negative 1.8% for next year.

Year-on-year quarterly revenue growth grew by 9.5%, now sitting on 45.19M for the twelve trailing months.

Volume

Today's last reported volume for National Bankshares is 5764 which is 83.94% below its average volume of 35887.

National Bankshares's sales growth for the next quarter is 8.1%. The company's growth estimates for the current quarter and the next is 52.2% and 6.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.86%.

Volatility

National Bankshares's last day, last week, and last month's current volatility was 0.61%, 0.70%, and 1.03%, respectively.

National Bankshares's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.11% (day), 1.93% (last week), and 2.25% (last month), respectively.

National Bankshares's Stock Yearly Top and Bottom Value

National Bankshares's stock is valued at $36.15 at 06:22 EST, below its 52-week high of $39.99 and way above its 52-week low of $23.37.

National Bankshares's Moving Average

National Bankshares's value is above its 50-day moving average of $35.27 and higher than its 200-day moving average of $34.81.

5. Autohome (ATHM)

7.3% sales growth and 18.96% return on equity

Autohome Inc. operates as an online destination for automobile consumers in the People's Republic of China.

Autohome's sales growth this year is expected to be 13.1% and 9.2% for next year.

Year-on-year quarterly revenue growth grew by 19.1%, now sitting on 8.95B for the twelve trailing months.

Volume

Today's last reported volume for Autohome is 1301690 which is 56.06% above its average volume of 834074.

Autohome's sales growth for the next quarter is 7.3%. The company's growth estimates for the current quarter and the next is a negative 19.1% and negative -28.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.96%.

Volatility

Autohome's last day, last week, and last month's current volatility was 3.36%, 3.85%, and 3.10%, respectively.

Autohome's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 10.01% (day), 6.75% (last week), and 4.93% (last month), respectively.

Autohome's Stock Yearly Top and Bottom Value

Autohome's stock is valued at $46.82 at 06:22 EST, way under its 52-week high of $147.67 and higher than its 52-week low of $43.04.

Autohome's Moving Average

Autohome's worth is way below its 50-day moving average of $59.76 and way under its 200-day moving average of $89.92.

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com